A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema

British Journal of Dermatology

Volumn 154, Issue 6, 2006, Pages 1137-1146

  Pitt, M ^a   Garside, R ^a   Stein, K ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atopic dermatitis; Cost utility analysis; Health economics; Immunosuppressant

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; PIMECROLIMUS;

APPLICATION SITE BURNING; ATOPIC DERMATITIS; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; HUMAN; PRIORITY JOURNAL; PRURITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; SKIN INFECTION; SKIN MANIFESTATION; SYSTEMATIC REVIEW;

ADULT; CHILD; COSTS AND COST ANALYSIS; DERMATITIS, ATOPIC; DRUG COSTS; DRUG THERAPY, COMBINATION; EMOLLIENTS; ENGLAND; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MARKOV CHAINS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33646557042     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07184.x     Document Type: Review

References (17)

1. Williams HC Strachan DP The natural history of childhood eczema: observations from the British 1958 birth cohort study Br J Dermatol 2003 139 834 9
2. Charman CR Morris AD Williams HC Topical corticosteroid phobia in patients with atopic eczema Br J Dermatol 2000 142 931 6
3. Ashcroft DM Dimmock P Garside R et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials BMJ 2005 330 516
4. Eichenfield LF Lucky AW Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents J Am Acad Dermatol 2002 46 495 504
5. Whalley D Huels J McKenna SP et al. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis Pediatrics 2002 110 1133 6
6. Wahn U Bos JD Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children Pediatrics 2002 110 E2
7. Meurer M Folster-Holst R Wozel G et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study Dermatology 2002 205 271 7
8. Luger T van Leent EJ Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis Br J Dermatol 2001 144 788 94
9. Weinstein MC O'Brien B Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies Value Health 2003 6 9 17
10. Finlay AY Measurement of disease activity and outcome in atopic dermatitis Br J Dermatol 1996 135 509 15
11. Stevens K Brazier J McKenna S et al. The development of a preference based measure of health in children with atopic eczema Sheffield Health Economics Group Discussion Paper No. 04/08 2005
12. The PenTAG Value of Health Panel website: (accessed 30 June 2005)
13. British Medical Association & Royal Pharmaceutical Society of Great Britain British National Formulary No. 49
14. Su JC Kemp AS Varigos GA et al. Atopic eczema: its impact on the family and financial cost Arch Dis Child 1997 76 159 62
15. Briggs AH Gray AM Handling uncertainty when performing economic evaluations of healthcare interventions Health Technol Assess 1999 3 1 134
16. Fenwick E Claxton K Sculpher M Representing uncertainty: the role of cost-effectiveness acceptability curves Health Econ 2001 10 779 87
17. U.S. Food and Drug Administration website: (accessed 12 October 2005)